{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-123807","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.176350+00:00","generated_at":"2026-06-07T17:14:42.707463+00:00","sec_items":["1.01","1.02","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioXcel Therapeutics amends credit agreement, terminates RIFA, lowers warrant exercise price to $3.6452","bullets":["Entered Second Amendment to Credit Agreement with Oaktree; converts $30M RIFA financing into Tranche A-2 Term Loan.","Increased OnkosXcel investment cap to $30.865M; pays 0.25% exit fee on loans repaid.","Reduces exercise price of existing warrants from $20.04 to $3.6452; issues new warrants for 69,630 shares at same price.","Terminates Revenue Interest Financing Agreement (RIFA); all future funding commitments cancelled."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-123807","json":"https://secwatch.observer/filing/0001104659-23-123807.json","markdown":"https://secwatch.observer/filing/0001104659-23-123807.md","text":"https://secwatch.observer/filing/0001104659-23-123807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T17:14:42.707463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cd39e2e430118510eb8a55b478ab98ad5e0a11d","claim":"BioXcel Therapeutics, Inc. amended term loan of The $30,000,000 in financing previously provided to the Company under the RIFA was converted to an outstanding loan unde with Lenders.","evidence_excerpt":"Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865,000 at any time outstanding in OnkosXcel Therapeutics, LLC (“OnkosXcel”), increased from $30,000,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"The $30,000,000 in financing previously provided to the Company under the RIFA was converted to an outstanding loan unde"},{"label":"Counterparty","value":"Lenders"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"27f717348405ee6bad1ba79e8b14ac3a06665811","claim":"BioXcel Therapeutics, Inc. terminated Revenue Interest Financing Agreement with the purchasers party thereto and Oaktree Fund Administration LLC (effective 2023-12-05).","evidence_excerpt":"the Company terminated the Revenue Interest Financing Agreement (as amended from time to time, the “RIFA”) by and among the Company, the purchasers party thereto (the “Purchasers”) and OFA, as administrative agent","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"the purchasers party thereto and Oaktree Fund Administration LLC"},{"label":"Effective","value":"2023-12-05"}],"fact_type":"material_agreement"},{"claim_id":"5350c99d75729d0e5f3341986e8cafe746ae5b69","claim":"BioXcel Therapeutics, Inc. amended Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement with Oaktree Fund Administration LLC and lenders valued at up to a maximum of $30,865,000 at any time outstanding (effective 2023-12-05).","evidence_excerpt":"BioXcel Therapeutics, Inc. (the “Company”) entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the “Second Amendment”), which amended the Credit Agreement and Guaranty","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oaktree Fund Administration LLC and lenders"},{"label":"Value","value":"up to a maximum of $30,865,000 at any time outstanding"},{"label":"Effective","value":"2023-12-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}